Thomas F. Gajewski to Antineoplastic Agents
This is a "connection" page, showing publications Thomas F. Gajewski has written about Antineoplastic Agents.
Connection Strength
1.959
-
STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019 07; 290(1):24-38.
Score: 0.300
-
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19; 11(7):1018-30.
Score: 0.225
-
New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 2015 Apr; 26(2):175-8.
Score: 0.220
-
Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature. J Immunol. 2014 Oct 15; 193(8):4254-60.
Score: 0.215
-
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.
Score: 0.190
-
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res. 2005 Nov 01; 11(21):7861-5.
Score: 0.116
-
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. J Immunother Cancer. 2023 06; 11(6).
Score: 0.098
-
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Eur J Cancer. 2020 03; 127:52-66.
Score: 0.078
-
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 02; 171(4):934-949.e16.
Score: 0.067
-
The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016 07 01; 126(7):2404-11.
Score: 0.061
-
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96.
Score: 0.055
-
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
Score: 0.054
-
Harnessing the immune response. Clin Adv Hematol Oncol. 2012 Jan; 10(1):46-8.
Score: 0.045
-
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81.
Score: 0.036
-
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J Immunother. 2007 Sep; 30(6):577-90.
Score: 0.033
-
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006 Jul 15; 119(2):317-27.
Score: 0.031
-
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006 Oct; 55(10):1185-97.
Score: 0.030
-
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005 Sep 01; 104(5):1045-8.
Score: 0.029
-
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004 Jul; 15(7):1109-14.
Score: 0.027
-
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014 Nov 20; 41(5):843-52.
Score: 0.014
-
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
Score: 0.012
-
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 03; 11:137.
Score: 0.012
-
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.
Score: 0.012